Related Experiment Video
Updated: May 16, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Triple Negative Breast Cancer and 68 Ga-Trivehexin : A Glance of Hope
Fahad Marafi1, Taibah Alahmad2, Mahmoud Alfeeli1
1Department of Nuclear Medicine, faculty of Allied health, Jaber Al Ahmad Center of Molecular imaging.
Abstract:
αvβ6 integrin is a heterodimeric transmembrane cell adhesive receptors that mediate cell-substratum adhesion and has been correlated to aggressiveness of various malignancies including breast cancer, with reduced progression-free survival. This integrin was found to facilitate tumor invasion, inhibit apoptosis, regulate expression of matrix metalloproteases, and activate TGF-β. Therefore, it could serve as a prognostic prob for tracking preinvasive tumor progression and monitoring the treatment variety of radiopharmaceuticals that target αvβ6-integrin, as well as its potential role as theranostic agent. Our case demonstrates the viability of 68 Ga-Trivehexin PET tracer in a case of histopathologically proven triple-negative breast cancer.
Insights
Alpha-v-beta-6 integrin (αvβ6) is linked to aggressive breast cancer. A novel PET tracer, 68Ga-Trivehexin, shows promise for imaging and potentially treating this malignancy.
Area of Science:
- Oncology
- Molecular Imaging
- Integrin Biology
Background:
- Alpha-v-beta-6 integrin (αvβ6) is a cell adhesion receptor implicated in various cancers, including breast cancer, correlating with poor prognosis.
- αvβ6 facilitates tumor invasion, inhibits apoptosis, and modulates matrix metalloproteinases and TGF-β signaling.
Purpose of the Study:
- To investigate the potential of αvβ6 integrin as a prognostic marker and theranostic target in breast cancer.
- To evaluate the utility of the novel positron emission tomography (PET) tracer 68Ga-Trivehexin for imaging αvβ6 in triple-negative breast cancer.
Main Methods:
- Case study of a patient with histopathologically confirmed triple-negative breast cancer.
- Utilized 68Ga-Trivehexin PET imaging to target αvβ6 integrin.
Main Results:
- The study demonstrated the feasibility of using 68Ga-Trivehexin PET tracer.
- This highlights the potential of αvβ6 as a theranostic target in triple-negative breast cancer.
Conclusions:
- Alpha-v-beta-6 integrin is a relevant target in aggressive breast cancer.
- 68Ga-Trivehexin PET imaging shows promise for theranostic applications in triple-negative breast cancer.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
